{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:05Z","timestamp":1792265045364,"version":"4.4.0"},"reference-count":45,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,7]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Immunotherapy has shown activity in patients with brain metastases (BM) and leptomeningeal disease (LMD). We have evaluated LMD and intraparenchymal control rates for patients with resected BM receiving postoperative stereotactic radiosurgery (SRS) and immunotherapy or postoperative SRS alone. We hypothesize that postoperative SRS and immunotherapy will result in a lower rate of LMD with acceptable toxicity compared with postoperative SRS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>One hundred and twenty-nine patients with non-small-cell lung cancer (NSCLC) and melanoma BM who received postoperative fractionated SRS (fSRS; 3\u00d79 Gy) in combination with immunotherapy or postoperative fSRS alone for completely resected BM were retrospectively evaluated. The primary endpoint of the study was the rate of LMD after treatments. The secondary endpoints were local failure, distant brain parenchymal failure (DBF), overall survival (OS), and treatment-related toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-three patients received postoperative SRS and immunotherapy, either nivolumab or pembrolizumab, and 66 patients received postoperative SRS alone to the resection cavity. With a median follow-up of 15 months, LMD occurred in 19 patients: fSRS group, 14; fSRS and immunotherapy, 5. The 12-month LMD cumulative rates were 22% (95% CI 14% to 37%) in the fSRS group and 6% (95% CI 2% to 17%) in the combined treatment group (p=0.007). Resection cavity control was similar between the groups, whereas DBF and OS were significantly different; the 1-year DBF rates were 31% (95% CI 20% to 46%) in the fSRS and immunotherapy group and 52% (95% CI 39% to 68%) in the fSRS group; respective OS rates were 78% (95% CI 67% to 88%) and 58.7% (95% CI 47% to 70%). Twenty-two patients undergoing postoperative fSRS and immunotherapy and nine subjected to postoperative fSRS experienced treatment-related imaging changes suggestive of radiation-induced brain necrosis (p=0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Postoperative fSRS in combination with immunotherapy decreases the incidence of LMD and DBF in patients with resected BM from NSCLC and melanoma as compared with fSRS alone, reducing the rate of neurological death and prolonging survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003730","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T12:07:24Z","timestamp":1640261244000},"page":"e003730","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03340129","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-1603","authenticated-orcid":false,"given":"Giuseppe","family":"Minniti","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy"},{"name":"IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-4743","authenticated-orcid":false,"given":"Luca","family":"Capone","sequence":"additional","affiliation":[{"name":"Radiation Oncology, UPMC Hillman Cancer Center San Pietro Hospital FBF, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Giraffa","sequence":"additional","affiliation":[{"name":"Radiation Oncology, UPMC Hillman Cancer Center San Pietro Hospital FBF, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Russo","sequence":"additional","affiliation":[{"name":"Radiation Oncology, UPMC Hillman Cancer Center Villa Maria, Mirabella Eclano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cicone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, \"Magna Graecia\" University of Catanzaroand Nuclear Medicine Unit, University Hospital \"Mater Domini\", Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bozzao","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, NESMOS Department, Sant'Andrea Hospital, La Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[{"name":"Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Ospedale Sacro Cuore Don Calabria Hospital, Negrar, Italy"},{"name":"University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[{"name":"Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Ospedale Sacro Cuore Don Calabria Hospital, Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Fineschi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Radiation Oncology, UPMC Hillman Cancer Center San Pietro Hospital FBF, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tufo","sequence":"additional","affiliation":[{"name":"Institute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bianciardi","sequence":"additional","affiliation":[{"name":"Radiation Oncology, UPMC Hillman Cancer Center San Pietro Hospital FBF, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierCarlo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery, and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Paolini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"2025100312154344000_9.12.e003730.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.17.1485"},{"key":"2025100312154344000_9.12.e003730.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1655"},{"key":"2025100312154344000_9.12.e003730.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30414-X"},{"key":"2025100312154344000_9.12.e003730.4","article-title":"Multidisciplinary patient-centered management of brain metastases and future directions","volume":"2","author":"Palmer","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2025100312154344000_9.12.e003730.5","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.ijrobp.2011.12.017","article-title":"Current dosing paradigm for stereotactic radiosurgery alone after surgical resection of brain metastases needs to be optimized for improved local control","volume":"83","author":"Prabhu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100312154344000_9.12.e003730.6","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000000148"},{"key":"2025100312154344000_9.12.e003730.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.03.037"},{"key":"2025100312154344000_9.12.e003730.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.09.051"},{"key":"2025100312154344000_9.12.e003730.9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3171\/2014.7.GKS141488","article-title":"Early gamma knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control","volume":"121","author":"Iorio-Morin","year":"2014","journal-title":"J Neurosurg"},{"key":"2025100312154344000_9.12.e003730.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30441-2"},{"key":"2025100312154344000_9.12.e003730.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.054"},{"key":"2025100312154344000_9.12.e003730.12","doi-asserted-by":"crossref","first-page":"E860","DOI":"10.1093\/neuros\/nyz162","article-title":"Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases","volume":"85","author":"Soliman","year":"2019","journal-title":"Neurosurgery"},{"key":"2025100312154344000_9.12.e003730.13","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jamaoncol.2020.4630","article-title":"Multi-Institutional analysis of prognostic factors and outcomes after Hypofractionated stereotactic radiotherapy to the resection cavity in patients with brain metastases","volume":"6","author":"Eitz","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100312154344000_9.12.e003730.14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2019.11.022","article-title":"Stereotactic radiosurgery for resected brain metastases: single-institutional experience of over 500 cavities","volume":"106","author":"Shi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100312154344000_9.12.e003730.15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13014-021-01802-9","article-title":"Current status and recent advances in resection cavity irradiation of brain metastases","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"2025100312154344000_9.12.e003730.16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx221"},{"key":"2025100312154344000_9.12.e003730.17","doi-asserted-by":"publisher","DOI":"10.3171\/2014.3.JNS131679"},{"key":"2025100312154344000_9.12.e003730.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.022"},{"key":"2025100312154344000_9.12.e003730.19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocn.2017.12.009","article-title":"Postoperative radiosurgery for the treatment of metastatic brain tumor: evaluation of local failure and leptomeningeal disease","volume":"49","author":"Foreman","year":"2018","journal-title":"J Clin Neurosci"},{"key":"2025100312154344000_9.12.e003730.20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of neurosurgical resection with development of pachymeningeal seeding in patients with brain metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312154344000_9.12.e003730.21","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz049"},{"key":"2025100312154344000_9.12.e003730.22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2019.10.002","article-title":"Nodular leptomeningeal Disease-A distinct pattern of recurrence after postresection stereotactic radiosurgery for brain metastases: a multi-institutional study of interobserver reliability","volume":"106","author":"Turner","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100312154344000_9.12.e003730.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30053-5"},{"key":"2025100312154344000_9.12.e003730.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"2025100312154344000_9.12.e003730.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"2025100312154344000_9.12.e003730.26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international metanalysis of individual patient data. Lehrer EJ, Peterson J, brown PD, et al. treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international metanalysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025100312154344000_9.12.e003730.27","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1007\/s00330-020-07514-0","article-title":"Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis","volume":"31","author":"Kim","year":"2021","journal-title":"Eur Radiol"},{"key":"2025100312154344000_9.12.e003730.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0918-0"},{"key":"2025100312154344000_9.12.e003730.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"2025100312154344000_9.12.e003730.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2886-4"},{"key":"2025100312154344000_9.12.e003730.31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0527"},{"key":"2025100312154344000_9.12.e003730.32","article-title":"Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery","volume":"3","author":"Teyateeti","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2025100312154344000_9.12.e003730.33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002473"},{"key":"2025100312154344000_9.12.e003730.34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv622"},{"key":"2025100312154344000_9.12.e003730.35","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0282-x"},{"key":"2025100312154344000_9.12.e003730.36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100312154344000_9.12.e003730.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.11.041"},{"key":"2025100312154344000_9.12.e003730.38","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0588-y"},{"key":"2025100312154344000_9.12.e003730.39","doi-asserted-by":"crossref","unstructured":"Long VG , Atkinson V , Lo S . Five-year overall survival from the anti-PD1 brain collaboration (ABC study): randomized phase 2 study of nivolumab or nivolumab + ipilimumab in patients with melanoma brain metastases. ASCO 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.9508"},{"key":"2025100312154344000_9.12.e003730.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.03.013"},{"key":"2025100312154344000_9.12.e003730.41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijrobp.2018.10.038","article-title":"Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials","volume":"103","author":"Lehrer","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100312154344000_9.12.e003730.42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100312154344000_9.12.e003730.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025100312154344000_9.12.e003730.44","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0156-7"},{"key":"2025100312154344000_9.12.e003730.45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijrobp.2020.04.023","article-title":"The promise of combining radiation therapy with immunotherapy","volume":"108","author":"Jagodinsky","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:15:51Z","timestamp":1759518951000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,23]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jitc-2021-003730"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003730","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}